Seeking huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging

Human Brain Mapping

Volumn 34, Issue 7, 2013, Pages 1625-1635

  Sánchez Castañeda, Cristina ^a,b   Cherubini, Andrea ^a   Elifani, Francesca ^c   Péran, Patrice ^a,d   Orobello, Sara ^c   Capelli, Giovanni ^e   Sabatini, Umberto ^a   Squitieri, Ferdinando ^c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

Author keywords

Anisotropy; Huntington disease; Iron; Mean diffusivity; MRI; Volume

Indexed keywords

IRON;

ADULT; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DISEASE MARKER; FEMALE; FRACTIONAL ANISOTROPY; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; NEUROIMAGING; NUCLEUS ACCUMBENS; PREDICTIVE VALUE; PRIORITY JOURNAL; PUTAMEN; RELAXATION TIME; STRUCTURE ANALYSIS; TEMPORAL LOBE; THALAMUS;

ADULT; ANALYSIS OF VARIANCE; ANISOTROPY; BASAL GANGLIA; BIOLOGICAL MARKERS; BRAIN MAPPING; CROSS-SECTIONAL STUDIES; DIFFUSION TENSOR IMAGING; DISEASE PROGRESSION; FEMALE; FERRITINS; HUMANS; HUNTINGTON DISEASE; IMAGING, THREE-DIMENSIONAL; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; REPRODUCIBILITY OF RESULTS;

EID: 84879229933     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22019     Document Type: Article

References (61)

1. Aylward E, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA (2004): Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63: 66-72.
2. Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, Barta PE, Pearlson GD, Ross CA (2000): Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 15: 552-560.
3. Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Long JD, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2011): Striatal Volume Contributes to the Prediction of Onset of Huntington Disease in Incident Cases. Biol Psychiatry (in press)
4. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, Johnson HJ, Magnotta VA, Juhl AR, Paulsen JS; PREDICT-HD Investigators and Coordinators of Huntington Study Group (2011): Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 82: 405-410.
5. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J (1999): Increased basal ganglia iron levels in Huntington disease. Arch Neurol 56: 569-574.
6. Bartzokis G, Lu PH, Tishler TA, Fong SM, Oluwadara B, Finn JP, Huang D, Bordelon Y, Mintz J, Perlman S (2007): Myelin breakdown and iron changes in Huntington's disease: Pathogenesis and treatment implications. Neurochem Res 32: 1655-1664.
7. Basser PJ, Pierpaoli C (1996): Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson 111: 209-219.
8. Brinkman RR, Mezei MM, Theilmann J, Almquist E, Hayden MR (1997): The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60: 1202-1210.
9. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ (2004): A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: Reliability and validation against manual measurement of total intracranial volume. Neuroimage 23: 724-738.
10. Cherubini A, Péran P, Caltagirone C, Sabatini U, Spalletta G (2009): Aging of subcortical nuclei: Microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 48: 29-36.
11. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F (2006): Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 47: 215-222.
12. Dexter DT, Jenner P, Schapira AH, Marsden CD (1992): Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 (Suppl): S94-S100.
13. Di Paola M, Di Iulio F, Cherubini A, Blundo C, Casini AR, Sancesario G, Passafiume D, Caltagirone C, Spalletta G (2010): When, where, and how the corpus callosum changes in MCI and AD: A multimodal MRI study. Neurology 74: 1136-1142.
14. Douaud G, Behrens TE, Poupon C, Cointepas Y, Jbabdi S, Gaura V, Golestani N, Krystkowiak P, Verny C, Damier P, Bachoud-Lévi AC, Hantraye P, Remy P (2009): In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage 46: 958-966.
15. Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C, Krystkowiak P, Damier P, Bachoud-Levi AC, Hantraye P, Remy P (2006): Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 32: 1562-1575.
16. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D (2007): Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 13: 2858-2867.
17. Folstein MF, Folstein SE, McHugh PR (1975): "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
18. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994): Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-807.
19. Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP, Myers RH (2001): Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 49: 29-34.
20. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999): Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci 19: 2522-2534.
21. Hilditch-Maguire P, Trettel F, Passani L, Auerbach A, Persichetti F, MacDonald ME (2000): Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles. Human Mol Genet 9: 2789-2797.
22. Hobbs NZ, Henley SM, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Tabrizi SJ, Fox NC (2009): Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington's disease. Neuroimage 47: 1659-1665.
23. Huntington Study Group (1996): The unified Huntington's disease rating scale: Reliability and consistency. Mov Dis 11: 136-142.
24. Jurgens CK, van de Wiel L, van Es AC, Grimbergen YM, Witjes-Ané MN, van der Grond J, Middelkoop HA, Roos RA (2008): Basal ganglia volume and clinical correlates in "preclinical" Huntington's disease. J Neurol 255: 1785-1791.
25. Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB (2004): Topography of cerebral atrophy in early Huntington's disease: A voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 75: 213-220.
26. Klöppel S, Draganski B, Golding CV, Chu C, Nagy Z, Cook PA, Hicks SL, Kennard C, Alexander DC, Parker GJ, Tabrizi SJ, Frackowiak RS (2008): White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 131: 196-204.
27. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004): A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65: 267-277.
28. Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, Fazekas F, Ropele S (2010): Quantitative MR imaging of brain iron: A postmortem validation study. Radiology 257: 455-462.
29. Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI (2007): Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet 16: 1905-1920.
30. Magnotta VA, Kim J, Koscik T, Beglinger LJ, Espinso D, Langbehn D, Nopoulos P, Paulsen JS (2009): Diffusion tensor imaging in preclinical Huntington's disease. Brain Imaging Behav 3: 77-84.
31. Mascalchi M, Lolli F, Della Nave R, Tessa C, Petralli R, Gavazzi C, Politi LS, Macucci M, Filippi M, Piacentini S (2004): Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 232: 867-873.
32. Moos T, Rosengren Nielsen T, Skjørringe T, Morgan EH (2007): Iron trafficking inside the brain. J Neurochem 103: 1730-1740.
33. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, Richardson EP Jr, Bird ED (1991): Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol 50: 729-742.
34. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I; Huntington Study Group (2001): Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57: 658-662.
35. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC (2006a) Brain structure in preclinical Huntington's disease. Biol Psychiatry 59: 57-63.
36. Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E; Predict-HD Investigators of the Huntington Study Group (2006b) Preparing for preventive clinical trials: The predict-HD study. Arch Neurol 63: 883-890.
37. Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006): Microglial activation correlates with severity in Huntington's disease: A clinical and PET study. Neurology 66: 1638-1643.
38. Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J (2005): Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study. J Neurol Sci 239: 11-19.
39. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997): CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41: 689-692.
40. Péran P, Cherubini A, Luccichenti G, Hagberg G, Démonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, Sabatini U (2009): Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp 30: 2667-2675.
41. Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U (2010): Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133: 3423-3433.
42. Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV (2010): Diffusion tensor imaging of deep gray matter brain structures: Effects of age and iron concentration. Neurobiol Aging 31: 482-493.
43. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM (2003): Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology 60: 1615-1620.
44. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH (2006): Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 21: 1317-1325.
45. Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F (2008): Longitudinal analysis of regional grey matter loss in Huntington's disease: Effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 79: 130-135.
46. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M (2001): Early and progressive accumulation of reactive microglia in the Huntington's disease brain. J Neuropathol Exp Neurol 60: 161-172.
47. Simmons DA, Casale M, Alcon B, Pham N, Narayan N, Lynch G (2007): Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 55: 1074-1084.
48. Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD (2003): Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126: 946-955.
49. Sritharan A, Egan GF, Johnston L, Horne M, Bradshaw JL, Bohanna I, Asadi H, Cunnington R, Churchyard AJ, Chua P, Farrow M, Georgiou-Karistianis N (2010): A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry 81: 257-262.
50. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC; TRACK-HD Investigators (2009): Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol 8: 791-801.
51. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators (2011): Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurol 10: 31-42.
52. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007): Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130: 1759-1766.
53. Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS (2002): The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 125: 1815-1828.
54. Van Camp N, Blockx I, Camón L, de Vera N, Verhoye M, Veraart J, Van Hecke W, Martínez E, Soria G, Sijbers J, Planas AM, Van der Linden A: A complementary diffusion tensor imaging (DTI)-histological study in a model of Huntington's disease. Neurobiol Aging (in press).
55. Vandenberghe W, Demaerel P, Dom R, Maes F (2009): Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J Neurol 256: 109-114.
56. Vonsattel JP (2008). Huntington disease models and human neuropathology: Similarities and differences. Acta Neuropathol 115: 55-69.
57. Vymazal J, Klempír J, Jech R, Zidovská J, Syka M, Růzicka E, Roth J (2007): MR relaxometry in Huntington's disease: Correlation between imaging, genetic and clinical parameters. J Neurol Sci 263: 20-25.
58. Wakai M, Takahashi A, Hashizume Y (1993): A histometrical study on the globus pallidus in Huntington's disease. J Neurol Sci 119: 18-27.
59. Walker FO (2007): Huntington's disease. Lancet 369: 220-221.
60. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA (2004): The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 101: 9843-9848.
61. Zhang X, Surguladze N, Slagle-Webb B, Cozzi A, Connor JR (2006): Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 54: 795-804.